<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34442798</PMID><DateRevised><Year>2021</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-2607</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>12</Day></PubDate></JournalIssue><Title>Microorganisms</Title><ISOAbbreviation>Microorganisms</ISOAbbreviation></Journal><ArticleTitle>Post-COVID-19 Syndrome: Nine Months after SARS-CoV-2 Infection in a Cohort of 354 Patients: Data from the First Wave of COVID-19 in Nord Franche-Comt&#xe9; Hospital, France.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1719</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/microorganisms9081719</ELocationID><Abstract><AbstractText>(1) Background.&amp;nbsp;Post-COVID-19 syndrome is defined as the persistence of symptoms after confirmed SARS-CoV-2 infection. (2) Methods. ANOSVID is an observational retrospective study in <i>Nord Franche-Comt&#xe9;</i> Hospital in France that included adult COVID-19 patients confirmed by RT-PCR from 1 March 2020 to 31 May 2020. The aim was to describe patients with post-COVID-19 syndrome with persistent symptoms (PS group) and to compare them with the patients without persistent symptoms (no-PS group). (3) Results. Of the 354 COVID-19 patients, 35.9% (<i>n</i> = 127) reported persistence of at least one symptom after a mean of 289.1 &#xb1; 24.5 days after symptom onset. Moreover, 115 patients reported a recurrence of symptoms after recovery, and only 12 patients reported continuous symptoms. The mean age of patients was 48.6 years (19-93) &#xb1; 19.4, and 81 patients (63.8%) were female. Patients in the PS group had a longer duration of symptoms of initial acute SARS-CoV-2 infection than patients in the no-PS group (respectively, 57.1 &#xb1; 82.1 days versus 29.7 &#xb1; 42.1 days, <i>p</i> &lt; 0.001). A majority of patients (<i>n</i> = 104, 81.9%) reported three or more symptoms. The most prevalent persistent symptoms were loss of smell (74.0%, <i>n</i> = 94), fatigue (53.5%, <i>n</i> = 68), loss of taste (31.5%, <i>n</i> = 40), and dyspnea (30.7%, <i>n</i> = 39). These were followed by pain symptoms (26.8% (<i>n</i> = 34), 26.0% (<i>n</i> = 33), 24.4% (<i>n</i> = 31); headache, arthralgia, and myalgia, respectively). More than half of patients reporting persistent symptoms (58%, <i>n</i> = 73) were healthcare workers (HCWs). Among outpatients, this population was more present in the PS group than the no-PS group ((86.6%) <i>n</i> = 71/82 versus (72.2%) <i>n</i> = 109/151, <i>p</i> = 0.012). Post-COVID-19 syndrome was more frequent in patients with a past history of chronic rhinosinusitis (8.7% (<i>n</i> = 11%) versus 1.3% (<i>n</i> = 3), <i>p</i> &lt; 0.001). No significant difference was found regarding clinical characteristics and outcome, laboratory, imaging findings, and treatment received in the two groups. (4) Conclusions. More than a third of our COVID-19 patients presented persistent symptoms after SARS-CoV-2 infection, particularly through loss of smell, loss of taste, fatigue, and dyspnea, with a high prevalence in HCWs among COVID-19 outpatients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zayet</LastName><ForeName>Souheil</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3177-9806</Identifier><AffiliationInfo><Affiliation>Infectious Disease Department, Nord Franche-Comt&#xe9; Hospital, 90400 Trevenans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zahra</LastName><ForeName>Hajer</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Diabetology and Endocrinology Department, Nord Franche-Comt&#xe9; Hospital, 90400 Trevenans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Royer</LastName><ForeName>Pierre-Yves</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Infectious Disease Department, Nord Franche-Comt&#xe9; Hospital, 90400 Trevenans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tipirdamaz</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Infectious Disease Department, Nord Franche-Comt&#xe9; Hospital, 90400 Trevenans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercier</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infectious Disease Department, Nord Franche-Comt&#xe9; Hospital, 90400 Trevenans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendrin</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-9220-9359</Identifier><AffiliationInfo><Affiliation>Infectious Disease Department, Nord Franche-Comt&#xe9; Hospital, 90400 Trevenans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lepiller</LastName><ForeName>Quentin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Virology Department, University Hospital of Besan&#xe7;on, 25000 Besan&#xe7;on, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marty-Quinternet</LastName><ForeName>Sol&#xe8;ne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Virology Department, University Hospital of Besan&#xe7;on, 25000 Besan&#xe7;on, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osman</LastName><ForeName>Molka</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9598-2486</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University Tunis El Manar, Tunis 1007, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belfeki</LastName><ForeName>Nabil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, Groupe Hospitalier Sud Ile de France, 77000 Melun, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toko</LastName><ForeName>Lynda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Infectious Disease Department, Nord Franche-Comt&#xe9; Hospital, 90400 Trevenans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garnier</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Microbiology Department, Nord Franche-Comt&#xe9; Hospital, 90400 Trevenans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierron</LastName><ForeName>Alix</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious Disease Department, Nord Franche-Comt&#xe9; Hospital, 90400 Trevenans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plantin</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Microbiology Department, Nord Franche-Comt&#xe9; Hospital, 90400 Trevenans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messin</LastName><ForeName>Louise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Infectious Disease Department, Nord Franche-Comt&#xe9; Hospital, 90400 Trevenans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villemain</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Microbiology Department, Nord Franche-Comt&#xe9; Hospital, 90400 Trevenans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouiller</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-2177-4318</Identifier><AffiliationInfo><Affiliation>Infectious Disease Department, University Hospital of Besan&#xe7;on, 25000 Besan&#xe7;on, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klopfenstein</LastName><ForeName>Timoth&#xe9;e</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Infectious Disease Department, Nord Franche-Comt&#xe9; Hospital, 90400 Trevenans, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Microorganisms</MedlineTA><NlmUniqueID>101625893</NlmUniqueID><ISSNLinking>2076-2607</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dyspnea</Keyword><Keyword MajorTopicYN="N">fatigue</Keyword><Keyword MajorTopicYN="N">follow-up</Keyword><Keyword MajorTopicYN="N">health care workers</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">post-COVID-19</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>27</Day><Hour>1</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34442798</ArticleId><ArticleId IdType="pmc">PMC8401026</ArticleId><ArticleId IdType="doi">10.3390/microorganisms9081719</ArticleId><ArticleId IdType="pii">microorganisms9081719</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Armange L., B&#xe9;n&#xe9;zit F., Picard L., Pronier C., Guillot S., Lentz P.-A., Carr&#xe9; F., Tattevin P., Revest M. Prevalence and characteristics of persistent symptoms after non-severe COVID-19: A prospective cohort study. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 2021:1&#x2013;5. doi: 10.1007/s10096-021-04261-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-021-04261-y</ArticleId><ArticleId IdType="pmc">PMC8064701</ArticleId><ArticleId IdType="pubmed">33893570</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen M.S., Kristiansen M.F., Hanusson K.D., Danielsen M.E., Steig B.&#xc1;., Gaini S., Str&#xf8;m M., Weihe P. Long COVID in the Faroe Islands: A Longitudinal Study among Nonhospitalized Patients. Clin. Infect. Dis. 2020:ciaa1792. doi: 10.1093/cid/ciaa1792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1792</ArticleId><ArticleId IdType="pmc">PMC7799340</ArticleId><ArticleId IdType="pubmed">33252665</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Osikomaiya B., Erinoso O., Wright K.O., Odusola A.O., Thomas B., Adeyemi O., Bowale A., Adejumo O., Falana A., Abdus-salam I., et al. &#x201c;Long COVID&#x201d;: Persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infect. Dis. 2021;21:304. doi: 10.1186/s12879-020-05716-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05716-x</ArticleId><ArticleId IdType="pmc">PMC7993075</ArticleId><ArticleId IdType="pubmed">33765941</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lancet Neurology Long COVID: Understanding the neurological effects. Lancet Neurol. 2021;20:247. doi: 10.1016/S1474-4422(21)00059-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00059-4</ArticleId><ArticleId IdType="pmc">PMC7969137</ArticleId><ArticleId IdType="pubmed">33743226</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton A., Olliaro P., Sigfrid L., Carson G., Paparella G., Hastie C., Kaushic C., Boily-Larouche G., Suett J.C., O&#x2019;Hara M. Long COVID: Tackling a multifaceted condition requires a multidisciplinary approach. Lancet Infect. Dis. 2021;21:601&#x2013;602. doi: 10.1016/S1473-3099(21)00043-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00043-8</ArticleId><ArticleId IdType="pmc">PMC7906694</ArticleId><ArticleId IdType="pubmed">33548193</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus  National Guidance for Post-COVID Syndrome Assessment Clinics.  [(accessed on 27 April 2021)]; Available online:  https://www.england.nhs.uk/coronavirus/publication/national-guidance-for-post-covid-syndrome-assessment-clinics/</Citation></Reference><Reference><Citation>Dennis A., Wamil M., Alberts J., Oben J., Cuthbertson D.J., Wootton D., Crooks M., Gabbay M., Brady M., Hishmeh L., et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: A prospective, community-based study. BMJ Open. 2021;11:e048391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., A&#x2019;Court C., Buxton M., Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-P&#xe9;rez O., Merino E., Leon-Ramirez J.-M., Andres M., Ramos J.M., Arenas-Jim&#xe9;nez J., Asensio S., Sanchez R., Ruiz-Torregrosa P., Galan I., et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J. Infect. 2021;82:378&#x2013;383. doi: 10.1016/j.jinf.2021.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.01.004</ArticleId><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Kelly J.D., Lu S., Goldberg S.A., Davidson M.C., Mathur S., Durstenfeld M.S., Spinelli M.A., Hoh R., Tai V., et al. Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19. MedRxiv Prepr. Serv. Health Sci. :2021. doi: 10.1101/2021.03.11.21252311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.11.21252311</ArticleId></ArticleIdList></Reference><Reference><Citation>Leth S., Gunst J.D., Mathiasen V., Hansen K., S&#xf8;gaard O., &#xd8;stergaard L., Jensen-Fangel S., Storgaard M., Agergaard J. Persistent Symptoms in Patients Recovering From COVID-19 in Denmark. Open Forum Infect. Dis. 2021;8:ofab042. doi: 10.1093/ofid/ofab042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab042</ArticleId><ArticleId IdType="pmc">PMC7928683</ArticleId><ArticleId IdType="pubmed">33875970</ArticleId></ArticleIdList></Reference><Reference><Citation>Riestra-Ayora J., Yanes-Diaz J., Esteban-Sanchez J., Vaduva C., Molina-Quiros C., Larran-Jimenez A., Martin-Sanz E. Long-term follow-up of olfactory and gustatory dysfunction in COVID-19: 6 months case-control study of health workers. Eur. Arch. Oto-Rhino-Laryngol. 2021:1&#x2013;7. doi: 10.1007/s00405-021-06764-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-021-06764-y</ArticleId><ArticleId IdType="pmc">PMC8004560</ArticleId><ArticleId IdType="pubmed">33774737</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet Lond. Engl. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Biguenet A., Bouiller K., Marty-Quinternet S., Brunel A.-S., Chirouze C., Lepiller Q. SARS-CoV-2 respiratory viral loads and association with clinical and biological features. J. Med. Virol. 2021;93:1761&#x2013;1765. doi: 10.1002/jmv.26489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26489</ArticleId><ArticleId IdType="pubmed">32889755</ArticleId></ArticleIdList></Reference><Reference><Citation>Meije Y., Duarte-Borges A., Sanz X., Clemente M., Ribera A., Ortega L., Gonz&#xe1;lez-P&#xe9;rez R., Cid R., Pareja J., Cantero I., et al. Long-term outcomes of patients following hospitalization for COVID-19: A prospective observational study. Clin. Microbiol. Infect. 2021;27:1151&#x2013;1157. doi: 10.1016/j.cmi.2021.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.04.002</ArticleId><ArticleId IdType="pmc">PMC8062910</ArticleId><ArticleId IdType="pubmed">33901667</ArticleId></ArticleIdList></Reference><Reference><Citation>Poenaru S., Abdallah S.J., Corrales-Medina V., Cowan J. COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: A narrative review. Ther. Adv. Infect. Dis. 2021;8 doi: 10.1177/20499361211009385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20499361211009385</ArticleId><ArticleId IdType="pmc">PMC8060761</ArticleId><ArticleId IdType="pubmed">33959278</ArticleId></ArticleIdList></Reference><Reference><Citation>McGroder C.F., Zhang D., Choudhury M.A., Salvatore M.M., D&#x2019;Souza B.M., Hoffman E.A., Wei Y., Baldwin M.R., Garcia C.K. Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length. Thorax. :2021. doi: 10.1136/thoraxjnl-2021-217031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2021-217031</ArticleId><ArticleId IdType="pmc">PMC8103561</ArticleId><ArticleId IdType="pubmed">33927016</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y., Zhou J., Ding X., Ling G., Yu S. Pulmonary fibrosis in critical ill patients recovered from COVID-19 pneumonia: Preliminary experience. Am. J. Emerg. Med. 2020;38:2134&#x2013;2138. doi: 10.1016/j.ajem.2020.05.120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2020.05.120</ArticleId><ArticleId IdType="pmc">PMC7368908</ArticleId><ArticleId IdType="pubmed">33071084</ArticleId></ArticleIdList></Reference><Reference><Citation>Czuba C. Nouveaux tableaux de maladie professionnelle de la COVID-19: Vers une reconnaissance plus facilit&#xe9;e? Arch. Mal. Prof. Environ. 2021;82:45&#x2013;49.</Citation></Reference><Reference><Citation>Havervall S., Rosell A., Phillipson M., Mangsbo S.M., Nilsson P., Hober S., Th&#xe5;lin C. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 among Health Care Workers. JAMA. 2021;325:2015&#x2013;2016. doi: 10.1001/jama.2021.5612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.5612</ArticleId><ArticleId IdType="pmc">PMC8027932</ArticleId><ArticleId IdType="pubmed">33825846</ArticleId></ArticleIdList></Reference><Reference><Citation>Zayet S., Royer P.-Y., Toko L., Pierron A., Gendrin V., Klopfenstein T. Recurrence of COVID-19 after recovery ? A case series in health care workers, France. Microbes Infect. 2021;23:104803. doi: 10.1016/j.micinf.2021.104803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2021.104803</ArticleId><ArticleId IdType="pmc">PMC7923857</ArticleId><ArticleId IdType="pubmed">33667643</ArticleId></ArticleIdList></Reference><Reference><Citation>Zayet S., Royer P.-Y., Toko L., Pierron A., Gendrin V., Klopfenstein T. Prolonged COVID 19 Outbreak and Psychological Response of Nurses in Italian Healthcare System: Cross-Sectional Study. Front. Psychol. 2021;12:608413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055826</ArticleId><ArticleId IdType="pubmed">33889106</ArticleId></ArticleIdList></Reference><Reference><Citation>Klopfenstein T., Kadiane-Oussou N., Toko L., Royer P.-Y., Lepiller Q., Gendrin V., Zayet S. Features of anosmia in COVID-19. Med. Mal. Infect. 2020;50:436&#x2013;439. doi: 10.1016/j.medmal.2020.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medmal.2020.04.006</ArticleId><ArticleId IdType="pmc">PMC7162775</ArticleId><ArticleId IdType="pubmed">32305563</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechien J.R., Chiesa-Estomba C.M., De Siati D.R., Horoi M., Le Bon S.D., Rodriguez A., Dequanter D., Blecic S., El Afia F., Distinguin L., et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): A multicenter European study. Eur. Arch. Oto-Rhino-Laryngol. 2020;277:2251&#x2013;2261. doi: 10.1007/s00405-020-05965-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-020-05965-1</ArticleId><ArticleId IdType="pmc">PMC7134551</ArticleId><ArticleId IdType="pubmed">32253535</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangash M.N., Owen A., Alderman J.E., Chotalia M., Patel J.M., Parekh D. COVID-19 recovery: Potential treatments for post-intensive care syndrome. Lancet Respir. Med. 2020;8:1071&#x2013;1073. doi: 10.1016/S2213-2600(20)30457-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30457-4</ArticleId><ArticleId IdType="pmc">PMC7550044</ArticleId><ArticleId IdType="pubmed">33058770</ArticleId></ArticleIdList></Reference><Reference><Citation>Martillo M.A., Dangayach N.S., Tabacof L., Spielman L.A., Dams-O&#x2019;Connor K., Chan C.C., Kohli-Seth R., Cortes M., Escalon M.X. Postintensive Care Syndrome in Survivors of Critical Illness Related to Coronavirus Disease 2019: Cohort Study From a New York City Critical Care Recovery Clinic. Crit. Care Med. :2021. doi: 10.1097/CCM.0000000000005014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000005014</ArticleId><ArticleId IdType="pubmed">33769771</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehgal K., Fadel H.J., Tande A.J., Pardi D.S., Khanna S. Outcomes in Patients with SARS-CoV-2 and Clostridioides difficile Coinfection. Infect. Drug Resist. 2021;14:1645&#x2013;1648. doi: 10.2147/IDR.S305349.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S305349</ArticleId><ArticleId IdType="pmc">PMC8089469</ArticleId><ArticleId IdType="pubmed">33953575</ArticleId></ArticleIdList></Reference><Reference><Citation>Chotpitayasunondh T., Fischer T.K., Heraud J.-M., Hurt A.C., Monto A.S., Osterhaus A., Shu Y., Tam J.S. Influenza and COVID-19: What does co-existence mean? Influenza Other Respir. Viruses. 2021;15:407&#x2013;412. doi: 10.1111/irv.12824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12824</ArticleId><ArticleId IdType="pmc">PMC8051702</ArticleId><ArticleId IdType="pubmed">33128444</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>